Literature DB >> 22422989

Acetylation: a novel link between double-strand break repair and autophagy.

Ghadeer Shubassi1, Thomas Robert, Fabio Vanoli, Saverio Minucci, Marco Foiani.   

Abstract

Histone deacetylase (HDAC) inhibitors are clinically relevant because they are used as anticancer drugs. Recent evidence sheds light on an intriguing connection among the DNA damage response (DDR), protein acetylation, and autophagy. HDAC inhibitors have been shown to counteract key steps in the cellular response to double-strand break formation by affecting checkpoint activation, homologous recombination-mediated repair of DNA lesions, and stability of crucial enzymes involved in resection of DNA ends. The degradation of the resection factors depends on autophagy, which plays a detrimental role when cells are in a hyperacetylated state and experience treatment with radiomimetic anticancer drugs. Future work will be required to further investigate the mechanisms underlying the link between acetylation, autophagy, and the DDR, as well as the significance of mTORC1 inhibitors, which are potent inducers of autophagy that are now used in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422989     DOI: 10.1158/0008-5472.CAN-11-3172

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

2.  HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.

Authors:  Laurence Booth; Jane L Roberts; Adam Conley; Nichola Cruickshanks; Thomas Ridder; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

3.  Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.

Authors:  Patrick M Long; Scott W Tighe; Heather E Driscoll; Karen A Fortner; Mariano S Viapiano; Diane M Jaworski
Journal:  J Cell Physiol       Date:  2015-08       Impact factor: 6.384

4.  Pazopanib and HDAC inhibitors interact to kill sarcoma cells.

Authors:  Seyedmehrad Tavallai; Hossein A Hamed; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

5.  A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Authors:  Bernard Omolo; Craig Carson; Haitao Chu; Yingchun Zhou; Dennis A Simpson; Jill E Hesse; Richard S Paules; Kristine C Nyhan; Joseph G Ibrahim; William K Kaufmann
Journal:  Cell Cycle       Date:  2013-03-01       Impact factor: 4.534

6.  Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.

Authors:  Yi Liao; Xiaojia Niu; Bailing Chen; Holly Edwards; Liping Xu; Chengzhi Xie; Hai Lin; Lisa Polin; Jeffrey W Taub; Yubin Ge; Zhihui Qin
Journal:  J Med Chem       Date:  2016-08-24       Impact factor: 7.446

7.  Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation.

Authors:  Hye Jin Shin; Jennifer DeCotiis; Mario Giron; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

8.  Twilight, a Novel Circadian-Regulated Gene, Integrates Phototropism with Nutrient and Redox Homeostasis during Fungal Development.

Authors:  Yi Zhen Deng; Ziwei Qu; Naweed I Naqvi
Journal:  PLoS Pathog       Date:  2015-06-23       Impact factor: 6.823

9.  Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Authors:  Ahrum Min; Seock-Ah Im; Debora Keunyoung Kim; Sang-Hyun Song; Hee-Jun Kim; Kyung-Hun Lee; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Tae-You Kim; Mark J O'Connor; Yung-Jue Bang
Journal:  Breast Cancer Res       Date:  2015-03-07       Impact factor: 6.466

Review 10.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.